Testosterone and Cardiovascular Risk: TRAVERSE Trial and New FDA Label Change
Mohit Khera, MD, MBA, MPH, discusses testosterone therapy and cardiovascular risk, focusing on the TRAVERSE trial and FDA label changes.
Read More
ABPM studies
- HOME
- MEETINGS
- AdMeTech Global Summit
- Innovations in Urologic Practice
- International Bladder Cancer Update Expert Forum
- International Bladder Cancer Update
- International Functional and Reconstructive Urology Update
- International Prostate Cancer Update
- Perspectives in Urology: Point-Counterpoint
- Ralph E. Hopkins Urology Seminar
- Southwest Prostate Cancer Symposium
- Urology Today
- CONTENT & COMMENTARIES
- EDUCATIONAL WEBINAR SERIES
- UROEDGE™ LEARNING CENTERS
- INDUSTRY PERSPECTIVES
- FACULTY
Select Page